PI3K/AKT/MTOR | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

10,131 results for “PI3K/AKT/MTOR”

Trials

View all 7176 →

Efficacy of Everolimus-containing Chemotherapy in HER2- mBC Patients With PI3K/AKT/mTOR Mutations Study

14 participants · First posted Sep 23, 2021

Everolimus in Castrated Resistant Prostate Cancer(CRPC)Patients With PI3K-AKT-mTOR Signaling Pathway Deficiency

120 participants · First posted Jul 9, 2018

Pharmacodynamic Study of BKM120 in Breast Cancer

20 participants · First posted Jan 20, 2012

Drugs

View all 708 →

PI3K/Akt/mTOR inhibitors (Endo/Jubilant Biosys)

PI3K/mTOR Inhibitor 8o

dual PI3K/mTOR inhibitors (cancer)

Organizations

View all 84 →

PINK PEARLS INC

United States

Teeter Motor Company

United States

TOYOTA MOTOR CORPORATION

Japan

News

View all 2163 →

Sensei Biotherapeutics Acquires Faeth Therapeutics for $200M to Advance PI3K/AKT/mTOR Pathway Inhibitor PIKTOR

Faeth Therapeutics Advances Novel Three-Pronged Approach for Metabolism-Driven Cancers with Promising Preclinical Results

Advanced Endometrial Cancer Pipeline Gains Momentum as ADCs, Immunotherapy and Targeted Combinations Reshape Treatment

Page 1 of 1014